Loading...
•
Sep 30, 2021
Lyell Immunopharma Q3 2021 Earnings Report
Lyell Immunopharma reported financial results for the third quarter of 2021 and provided business highlights.
Key Takeaways
Lyell Immunopharma reported a net loss of $48.9 million for the third quarter of 2021, compared to a net loss of $35.7 million for the same period in 2020. The company's cash and investments were $936.4 million as of September 30, 2021.
Advanced multi-modality pipeline remains on track.
Preparing to initiate multiple clinical trials incorporating two platforms.
Cash and investments of $936.4 million as of September 30, 2021.
Plan to submit four INDs by the end of 2022.
Lyell Immunopharma
Lyell Immunopharma
Forward Guidance
Lyell anticipates progress in business plans, business strategy and planned clinical trials, plans to submit four INDs, potential clinical benefits and therapeutic potential of Lyell’s product candidates.
Positive Outlook
- Lyell’s anticipated progress.
- Lyell’s business plans
- Lyell’s business strategy
- Lyell’s planned clinical trials
- Potential clinical benefits and therapeutic potential of Lyell’s product candidates
Challenges Ahead
- Effects of the evolving COVID-19 pandemic
- Lyell’s ability to submit planned INDs on the anticipated timing or at all
- Initiation of planned clinical trials and enrollment of patients in its future clinical trials
- Lyell’s ability to manufacture and supply its product candidates for its future clinical trials
- The preclinical profiles of Lyell’s product candidates not translating in clinical trials